At Aragen, we are dedicated to advancing oncology research by offering comprehensive pre-clinical efficacy testing solutions designed to accelerate the development of breakthrough cancer therapies. Our expertise spans validated tumor models, including cell-line-derived xenografts (CDX), robust capabilities in imaging, biomarker analysis, and pharmacokinetics, and support for diverse therapeutic modalities like small molecules, biologics, and combination therapies. With tailored study designs and a focus on precision, we empower our partners to navigate the complexities of oncology drug development with speed and confidence. Together, we aim to make a meaningful difference in the fight against cancer. To know more about our services or to schedule a meeting with our experts write to us at [email protected] #oncologyresearch #drugdevelopment #biomarkers #biologics #preclinical #cdmo #cro #pharmaservices #xenografts #efficacytesting
High Impact Sustainability, EHS & Business Process Excellence Professional in Leadership Position
4dOur validated tumour models, including CDX and PDX, allow us to provide highly predictive pre-clinical insights, bridging the gap between discovery and clinical application.